keyword
MENU ▼
Read by QxMD icon Read
search

Neuroendocrine tumour

keyword
https://www.readbyqxmd.com/read/27904871/in-vivo-measurement-and-characterization-of-a-novel-formulation-of-177-lu-dota-octreotate
#1
Dale L Bailey, Thomas M Hennessy, Kathy P Willowson, E Courtney Henry, David Lh Chan, Alireza Aslani, Paul J Roach
OBJECTIVES: Lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as "No Carrier Added" (NCA) (177)Lu. We have radiolabelled DOTA-conjugated peptide DOTA-(Tyr(3))-octreotate with NCA (177)Lu ("NCA-LuTATE") and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. In this paper, we report on our initial studies on aspects of the biodistribution and dosimetry of NCA-LuTATE from gamma camera 2D whole body (WB) and quantitative 3D SPECT (qSPECT) (177)Lu imaging...
2016: Asia Oceania Journal of Nuclear Medicine & Biology
https://www.readbyqxmd.com/read/27897767/-she-has-given-me-the-confidence-and-strength-to-get-through-this
#2
(no author information available yet)
Since I was diagnosed with a neuroendocrine tumour in June 2011, my upper gastrointestinal specialist nurse Eleanor Church has been a pillar of support. She is so cheerful, warm, kind and compassionate that I actually look forward to my oncology appointments at Bedford Hospital.
November 16, 2016: Nursing Standard
https://www.readbyqxmd.com/read/27890514/effectiveness-of-radiolabelled-somatostatin-analogues-90-y-dotatoc-and-177-lu-dotatate-in-patients-with-metastatic-neuroendocrine-tumours-a-single-centre-experience-in-mexico
#3
S S Medina-Ornelas, F O García-Pérez
OBJECTIVE: To determine the effectiveness of therapy with the radiolabelled somatostatin analogues, (90)Y-DOTATOC and (177)Lu-DOTATATE, in the treatment of metastatic neuroendocrine tumours with progression to first-line treatment. MATERIAL AND METHODS: A study was conducted on 30 patients diagnosed with neuroendocrine tumours (gastroenteropancreatic, bronchopulmonary, MEN2A, MEN2B, phaeochromocytoma, and paraganglioma) with metastatic disease diagnosed by the pathology department, with progression to first-line treatment, and recruited from December 2014 to February 2016...
November 24, 2016: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/27890421/contrast-enhanced-mdct-in-patients-with-pancreatic-neuroendocrine-tumours-correlation-with-histological-findings-and-diagnostic-performance-in-differentiation-between-tumour-grades
#4
E Belousova, G Karmazanovsky, A Kriger, D Kalinin, L Mannelli, A Glotov, N Karelskaya, O Paklina, A Kaldarov
AIM: To identify the multidetector computed tomography (MDCT) features of pancreatic neuroendocrine tumours (pNETs), which correlate with tumour histology and enable preoperative grading. MATERIALS AND METHODS: Thirty-nine patients with histologically confirmed pNET who underwent preoperative contrast-enhanced MDCT were included in this study. Nineteen tumours were classified as Grade 1 (G1) and 20 as Grade 2 (G2). Histopathology slides were reviewed to assess the intratumoural microvascular density (MVD) and the amount of tumour stroma...
November 24, 2016: Clinical Radiology
https://www.readbyqxmd.com/read/27889527/-177-lu-dotatate-treatment-in-neuroendocrine-tumours-a-preliminary-study
#5
I Hervás, P Bello, M Falgas, M I Del Olmo, I Torres, C Olivas, V Vera, P Oliván, A M Yepes
Therapy with radiolabelled somatostatin analogue peptides is a promising new therapy to treat neuroendocrine tumours. The aim of this preliminary study is to present our experience with (177)Lu-DOTATATE therapy, and evaluate tolerability and short-term efficacy in patients with tumours expressing somatostatin receptors. A total of 7 patients with metastatic neuroendocrine tumours were treated, each with 4 doses of (177)Lu-DOTATATE. The treatment response was evaluated in the form of biochemical response (tumour markers), imaging methods (somatostatin receptor scintigraphy, computed tomography, and magnetic resonance), and functional and quality of life responses using the Karnofsky performance status scale...
November 23, 2016: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/27881473/clinicopathological-features-of-neoplasms-with-neuroendocrine-differentiation-occurring-in-the-liver
#6
Yoriko Nomura, Osamu Nakashima, Jun Akiba, Sachiko Ogasawara, Shogo Fukutomi, Rin Yamaguchi, Hironori Kusano, Masayoshi Kage, Koji Okuda, Hirohisa Yano
BACKGROUND/AIMS: We investigated the clinicopathological features of hepatic neuroendocrine tumours (NET) and neuroendocrine carcinoma (NEC), which remain largely unknown. MATERIAL AND METHODS: We examined 1235 tumours from 1048 patients who had undergone curative hepatectomy for liver neoplasms at Kurume University Hospital. Pathological diagnoses were based on the 2010 WHO Classification of Tumours of the Digestive System. We performed immunostaining for hepatocyte markers (eg, hepatocyte paraffin (HepPar)-1), neuroendocrine markers (eg, chromogranin A (CGA)) and the proliferation marker (Ki-67)...
November 23, 2016: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/27878790/additional-malignancies-in-patients-with-neuroendocrine-tumours-analysis-of-the-swissnet-registry
#7
Attila Kollár, Annika Blank, Aurel Perren, Lukas Bütikofer, Christoph Stettler, Emanuel Christ
PRINCIPLES: Neuroendocrine neoplasms (NENs) are believed to be associated with an increased risk for additional malignancies (AMs). We aimed to (1) assess the occurrence of AM in NEN patients (2) investigate the characteristics and temporal relationship of NEN patients with and without AM. METHODS: The SwissNET registry has prospectively documented patients with NEN since 2008, covering the entire area of Switzerland. Clinical characteristics, functionality, location and histology of NEN as well as survival of all consecutive patients were retrieved...
2016: Swiss Medical Weekly
https://www.readbyqxmd.com/read/27875519/expression-of-somatostatin-receptors-2-and-5-in-circulating-tumour-cells-from-patients-with-neuroendocrine-tumours
#8
Alexa Childs, Clare Vesely, Leah Ensell, Helen Lowe, Tu Vinh Luong, Martyn E Caplin, Christos Toumpanakis, Christina Thirlwell, John A Hartley, Tim Meyer
BACKGROUND: Neuroendocrine tumours (NET) overexpress somatostatin receptors (SSTR) that can be targeted for therapy. Somatostatin receptor expression is routinely measured by molecular imaging but the resolution is insufficient to define heterogeneity. We hypothesised that SSTR expression could be measured on circulating tumour cells (CTCs) and used to investigate heterogeneity of expression and track changes during therapy. METHODS: MCF-7 cells were transfected with SSTR2 or 5 and spiked into donor blood for analysis by CellSearch...
November 22, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27873319/lung-neuroendocrine-tumours-deep-sequencing-of-the-four-who-histotypes-reveals-chromatin-remodelling-genes-as-major-players-and-a-prognostic-role-for-tert-rb1-men1-and-kmt2d
#9
Michele Simbolo, Andrea Mafficini, Katarzyna O Sikora, Matteo Fassan, Stefano Barbi, Vincenzo Corbo, Luca Mastracci, Borislav Rusev, Federica Grillo, Caterina Vicentini, Roberto Ferrara, Sara Pilotto, Federico Davini, Giuseppe Pelosi, Rita T Lawlor, Marco Chilosi, Giampaolo Tortora, Emilio Bria, Gabriella Fontanini, Marco Volante, Aldo Scarpa
Next-generation sequencing (NGS) was applied to 148 lung neuroendocrine tumours (LNET) comprising the 4 WHO classification categories: 53 typical carcinoid (TC), 35 atypical carcinoid (AC), 27 large cell neuroendocrine carcinoma (LCNEC), and 33 small cell lung carcinoma (SCLC). A discovery screen was conducted on 46 samples using whole-exome sequencing and high-coverage targeted sequencing of 418 genes. Eighty-eight recurrently mutated genes from both the discovery screen and current literature were verified in the 46 cases of the discovery screen and validated on additional 102 LNET by targeted NGS, and their prevalence was evaluated on the whole series...
November 22, 2016: Journal of Pathology
https://www.readbyqxmd.com/read/27863693/surgical-treatment-of-non-functioning-pancreatic-neuroendocrine-tumours-based-on-three-clinical-scenarios
#10
Juli Busquets, Elena Ramírez-Maldonado, Teresa Serrano, Núria Peláez, Luís Secanella, Sandra Ruiz-Osuna, Emilio Ramos, Laura Lladó, Juan Fabregat
INTRODUCTION: The treatment of patients with non-functioning pancreatic neuroendocrine tumours (NFPNET) is resection in locally pancreatic disease, or with resectable liver metastases. There is controversy about unresectable liver disease. METHODS: We analysed the perioperative data and survival outcome of 63 patients who underwent resection of NFPNET between 1993 and 2012. They were divided into 3 scenarios: A, pancreatic resection (44patients); B, pancreatic and liver resection in synchronous resectable liver metastases (12patients); and C, pancreatic resection in synchronous unresectable liver metastases (6patients)...
November 15, 2016: Cirugía Española
https://www.readbyqxmd.com/read/27861745/clinical-signs-of-fibrosis-in-small-intestinal-neuroendocrine-tumours
#11
K Daskalakis, A Karakatsanis, P Stålberg, O Norlén, P Hellman
BACKGROUND: In patients with small intestinal neuroendocrine tumours (SI-NETs), serotonin and other cytokines released from tumour cells may induce fibrosis, leading to carcinoid heart disease and abdominal fibrotic reactions. The aim of this study was to assess the prevalence, clinical complications and management of this reaction in the abdomen. METHODS: This was a retrospective cohort study of patients with SI-NETs diagnosed between 1985 and 2015. Clinical data, outcomes, radiological findings, and surgical and radiological interventions were reviewed...
November 10, 2016: British Journal of Surgery
https://www.readbyqxmd.com/read/27860085/clinical-profile-and-treatment-outcomes-of-advanced-neuroendocrine-tumours-in-rural-and-regional-patients-a-retrospective-study-from-a-regional-cancer-center-in-north-queensland-australia
#12
Umbreen Hafeez, Abhishek Joshi, Manoj Bhatt, Jenny Kelly, Sabe Sabesan, Venkat Vangaveti
AIM: To study the clinical profile, treatment and survival outcomes for advanced neuroendocrine tumour (NET) patients in Australian regional and remote settings. METHODS: We reviewed all adult patients who were diagnosed with NETs between 1994 and 2012. Patients' data was extracted from electronic databases of The Townsville Cancer Centre. Remoteness was based on postcodes with patients stratified as regional or rural North Queensland according to Australian Standard Geographical Classification (ASGC)...
November 16, 2016: Internal Medicine Journal
https://www.readbyqxmd.com/read/27859268/heterogeneity-of-colorectal-cancer-risk-by-tumour-characteristics-large-prospective-study-of-uk-women
#13
Andrea Burón Pust, Rupert Alison, Roger Blanks, Kirstin Pirie, Kezia Gaitskell, Isobel Barnes, Toral Gathani, Gillian Reeves, Valerie Beral, Jane Green
Associations between behavioural and other personal factors and colorectal cancer risk have been reported to vary by tumour characteristics, but evidence is inconsistent. In a large UK-based prospective study we examined associations of 14 postulated risk factors with colorectal cancer risk overall, and across 3 anatomical sites and 4 morphological subtypes. Among 1.3 million women, 18,518 incident colorectal cancers were identified during 13.8 (SD 3.4) years follow-up via record linkage to national cancer registry data...
November 18, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27848218/evaluation-of-diagnostic-and-prognostic-significance-of-ki-67-index-in-pulmonary-carcinoid-tumours
#14
V Clay, G Papaxoinis, B Sanderson, J W Valle, M Howell, A Lamarca, P Krysiak, P Bishop, D Nonaka, W Mansoor
BACKGROUND: Pulmonary carcinoid (PC) tumours are classified as either typical (TC) or atypical (AC) according to mitotic index (MI) and presence of necrosis. The aim of this study was to analyse the diagnostic and prognostic values of the Ki-67 index in PC. METHODS/PATIENTS: Between January 2001 and March 2015, we evaluated 94 consecutive patients with a confirmed diagnosis of TC (n = 75) or AC (n = 19) at our institution. Diagnostic histology was centrally reviewed by a local expert neuroendocrine pathologist, with assessment of Ki-67, MI, and necrosis...
November 15, 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27830764/neuroblastoma
#15
Katherine K Matthay, John M Maris, Gudrun Schleiermacher, Akira Nakagawara, Crystal L Mackall, Lisa Diller, William A Weiss
Neuroblastoma is the most common extracranial solid tumour occurring in childhood and has a diverse clinical presentation and course depending on the tumour biology. Unique features of these neuroendocrine tumours are the early age of onset, the high frequency of metastatic disease at diagnosis and the tendency for spontaneous regression of tumours in infancy. The most malignant tumours have amplification of the MYCN oncogene (encoding a transcription factor), which is usually associated with poor survival, even in localized disease...
November 10, 2016: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/27822951/rectal-neuroendocrine-neoplasia-a-rare-tumour
#16
Marina de Benito Sanz, Javier Santos Fernández, Mª Henar Núñez Rodríguez
Colorectal neuroendocrine tumours are rare A 78 year old man with a history of hypertension, heart disease, pacemakers, prostate adenocarcinoma.On examination for rectal bleeding, a colonoscopy was performed and at 5 cm of the anal margin a 28 mm ulcerated neoformation was found.An echo-endoscopy revealed infiltration of the muscular layer with an area of loss in the cleavage plane loss and fraying of the perirectal fat infiltration suggestive of infiltration (T3). They no lymph nodes or metastasis were identified by CAT...
November 8, 2016: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/27821081/management-of-controversial-gastroenteropancreatic-neuroendocrine-tumour-clinical-situations-with-somatostatin-analogues-results-of-a-delphi-questionnaire-panel-from-the-netpraxis-program
#17
Isabel Sevilla, Ángel Segura, Jaume Capdevila, Carlos López, Rocío García-Carbonero, Enrique Grande
BACKGROUND: There are clinical situations (CS) in which the use of somatostatin analogs (SSAs) in patients with neuroendocrine tumors (NET) is controversial due to lack of evidence. A Delphi study was conducted to develop common treatment guidelines for these CS, based on clinical practice and expert opinion of Spanish oncologists. METHODS: A scientific committee identified 5 CS with a common core (c-c) [non-functioning NET, not susceptible of surgery/locoregional therapy, Ki67 < 10 % (except for CS5: >10 %), ECOG ≤ 2], and controversy regarding use of SSAs, and prepared a Delphi questionnaire of 48 treatment statements...
November 7, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27818210/neuroendocrine-tumours-emerge-from-the-shadows
#18
Judith A Gilbert
No abstract text is available yet for this article.
November 3, 2016: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/27817224/telotristat-ethyl-a-new-option-for-the-management-of-carcinoid-syndrome
#19
Angela Lamarca, Jorge Barriuso, Mairéad G McNamara, Richard A Hubner, Juan W Valle
Many patients with neuroendocrine tumour-related carcinoid syndrome treated with somatostatin analogues (SSA) won't achieve adequate symptom relief with the SSA alone; new treatment options are required. Telotristat ethyl is a tryptophan hydroxylase inhibitor, developed for the treatment of carcinoid syndrome. Areas covered: This review summarises the evidence supporting the role of telotristat ethyl in the management of carcinoid syndrome. Rationale, pharmacodynamics, pharmacokinetics, metabolism, clinical experience, efficacy and toxicity profiles are covered...
November 16, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27811856/predictive-factors-of-antiproliferative-activity-of-octreotide-lar-as-first-line-therapy-for-advanced-neuroendocrine-tumours
#20
Faidon-Marios Laskaratos, Martin Walker, Keval Naik, Emmanouil Maragkoudakis, Nikolaos Oikonomopoulos, Lee Grant, Tim Meyer, Martyn Caplin, Christos Toumpanakis
BACKGROUND: The antiproliferative activity of octreotide LAR in neuroendocrine tumours (NETs) has been demonstrated by small retrospective studies and confirmed by a prospective phase III trial (PROMID). However, there are limited data about the duration and predictors of response. The aim of our retrospective study was to determine the time to radiological progression (TTRP) of disease and the factors that were associated with better response. METHODS: A total of 254 treatment naïve patients with advanced NETs and positive somatostatin receptor scintigraphy were included...
November 22, 2016: British Journal of Cancer
keyword
keyword
13159
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"